Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30 results about "Adenosine kinase" patented technology

Adenosine kinase (AdK; EC 2.7.1.20) is an enzyme that catalyzes the transfer of gamma-phosphate from Adenosine triphosphate (ATP) to adenosine (Ado) leading to formation of Adenosine monophosphate (AMP). In addition to its well-studied role in controlling the cellular concentration of Ado, AdK also plays an important role in the maintenance of methylation reactions. All S-adenosylmethionine-dependent transmethylation reactions in cells lead to production of S-adenosylhomocysteine (SAH), which is cleaved by SAH hydrolase into Ado and homocysteine. The failure to efficiently remove these end products (Ado removed by phosphorylation by AdK) can result in buildup of SAH, which is a potent inhibitor of all transmethylation reactions. The disruption of AdK gene (-/-) in mice causes neonatal hepatic steatosis, a fatal condition characterized by rapid microvesicular fat infiltration, leading to early postnatal death. The liver was the main organ affected in these animals and in it the levels of adenine nucleotides were decreased, while those of SAH were elevated. Recently, missense mutations in the AdK gene in humans which result in AdK deficiency have also been shown to cause hypermethioninemia, encephalopathy and abnormal liver function.

Beta-cell replication promoting compounds and methods of their use

InactiveUS20130023491A1Easy to copyRaise the ratioBiocideOrganic chemistryS-adenosylhomocysteine HydrolaseCell biology
In the invention provides for a method of stimulating or increasing β-cell replication or growth, by contacting a β-cell with an inhibitor of adenosine kinase (ADK), an inhibitor of S-Adenosylhomocysteine hydrolase (SAHH) or an activator of AMP activated protein kinase (AMPK).
Owner:JOSLIN D ABETES CENTER INC +2

Enzyme composition for preparing nicotinamide mononucleotide and method for preparing nicotinamide mononucleotide by enzymatic process

The invention relates to the technical fields of biopharmacy and biochemical industry, and in particular relates to an enzyme composition for preparing nicotinamide mononucleotide and a method for preparing the nicotinamide mononucleotide by an enzymatic process. The enzyme composition is composed of adenosine kinase, adenine phosphoribosyl transferase and nicotinamide phosphoribosyl transferase.The three enzymes provided by the invention can be reasonably combined for efficient catalytic preparation of the nicotinamide mononucleotide. The enzyme composition provided by the invention can be recycled, has low costs, saves energy and protects the environment; the method for preparing the nicotinamide mononucleotide by the enzymatic process provided by the invention uses adenosine as a substrate, the enzyme composition is added, so that the nicotinamide mononucleotide can be prepared at low cost, safely and reliably, the cost of a current route can be reduced, and the method can be suitable for large-scale production and provides guarantee for the use of the nicotinamide mononucleotide in the fields of biocatalysis and drugs.
Owner:杭州唯泰生物药业有限公司 +1

Recombinant expression vector, recombinant expression host and method for synthesizing ATP (adenosine triphosphoric acid) from recombinant expression host

The invention belongs to the field of bioengineering, relates to preparation of ATP (adenosine triphosphoric acid), and provides a recombinant expression vector and a recombinant expression host containing the same. The recombinant expression vector contains polynucleotide of encoded adenosine kinase, adenylate kinase and acetokinase. The invention further provides a method for synthesizing ATP from the recombinant expression host. According to the invention, ATP is synthesized from the recombinant expression host by whole-cell catalysis, adenosine conversion rate, ATP yield and reaction efficiency are increased, and the reaction system contains simple components and is low in cost.
Owner:ZHEJIANG HISUN PHARMA CO LTD

Method for preparing nicotinamide adenine dinucleotide by virtue of enzyme method

InactiveCN111154821ASafe preparationLow costFermentationAdenine phosphoribosyltransferaseAdenosine
The invention belongs to the technical fields of biological pharmacy and biochemical engineering and discloses an enzyme composition for preparing nicotinamide adenine dinucleotide and a method for preparing the nicotinamide adenine dinucleotide by virtue of an enzyme method. The enzyme composition consists of adenosine kinase, adenine phosphoribosyltransferase, nicotinamide phosphoribose transferase and nicotinamide mononucleotide adenosine transferase. By virtue of reasonable combination of four enzymes, the nicotinamide adenine dinucleotide can be prepared through efficient catalysis. The enzyme composition can be circularly utilized and is low in cost, energy-saving and environment-friendly. According to the method for preparing the nicotinamide adenine dinucleotide by virtue of the enzyme method, adenosine is taken as a substrate, and the enzyme composition is added, so that the nicotinamide adenine dinucleotide can be safely and reliably prepared in a low-cost way, the cost of anexisting route is lowered, the existing route is applicable to large-scale production, and the use of the nicotinamide adenine dinucleotide in the fields of biological catalysis and drugs is guaranteed.
Owner:杭州唯泰生物药业有限公司 +1

Therapeutic delivery of adenosine into a tissue

The present invention relates to generation of embryonic stem cells and neural cells having deficient adenosine kinase gene on both alleles. The present invention further relates to methods of cell-based therapeutic delivery of agents and cells to a host tissue site for treatment of diseases.
Owner:LIFE & BRAIN

Methods of Identifying Compounds that Modulate IL-4 Receptor-Mediated IgE Synthesis Utilizing an Adenosine Kinase

InactiveUS20070054862A1Organic active ingredientsPeptide/protein ingredientsIl 4 receptorSurrogate analyte
The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize an adenosine kinase as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
Owner:RIGEL PHARMA

Beta-cell replication promoting compounds and methods of their use

In the invention provides for a method of stimulating or increasing beta-cell replication or growth, by contacting a beta-cell with an inhibitor of adenosine kinase (ADK), an inhibitor of S-Adenosylhomocysteine hydrolase (SAHH) or an activator of AMP activated protein kinase (AMPK).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +2

Composition for preventing or treating sepsis or septic shock comprising adk protein as active ingredient

The present invention relates to a composition for preventing or treating sepsis or septic shock including a Mycobacterium tuberculosis-derived adenosine kinase (ADK) protein as an active ingredient. The Mycobacterium tuberculosis-derived ADK protein according to one exemplary embodiment of the present invention has an effect of inhibit binding between the LPS and cells by binding to LPS, and also has an excellent therapeutic effect against sepsis by enhancing viability in a sepsis animal model and suppressing inflammatory response in the lung and cell death in the spleen.
Owner:KONKUK UNIV GLOCAL IND ACADEMIC COLLABORATION FOUND

Antibacterial composition containing adk protein as active ingredient, or composition for preventing or treating sepsis

The present invention relates to an antibacterial composition containing, as an active ingredient, adenylate kinase or adenosine kinase (ADK) protein derived from Mycobacterium tuberculosis, and a composition for preventing or treating infectious diseases. In addition, the present invention relates to a composition for preventing or treating sepsis or septic shock. Furthermore, the present invention relates to a method for preventing, improving or treating an infectious disease comprising administering the present antibacterial composition. The ADK protein derived from Mycobacterium tuberculosis according to the present invention has excellent antibacterial activity selectively against gram-negative bacteria, and thus can be favorably used as an antibacterial composition against gram-negative bacteria or for the prevention or treatment of infectious diseases caused by gram-negative bacteria. In addition, the ADK protein has an excellent sepsis treatment effects, thus can be favorably used for the prevention or treatment of sepsis or septic shock.
Owner:KONKUK UNIV GLOCAL IND ACADEMIC COLLABORATION FOUND

Cell-Free Expression System Having Novel Inorganic Polyphosphate-Based Energy Regeneration

The invention relates to an in vitro cell-free expression system incorporating a novel inorganic polyphosphate-based energy regeneration system. In certain embodiments, the invention includes a cell-free expression system where the cellular energy source, ATP, is regenerated from inorganic polyphosphate using a dual enzyme system. In this embodiment, this dual enzyme system may include thermostable Adenosyl Kinase, and / or Polyphosphate Kinase enzymes.
Owner:NATURES TOOLBOX INC

Cell-Free Expression System Having Novel Inorganic Polyphosphate-Based Energy Regeneration

The invention relates to an in vitro cell-free expression system incorporating a novel inorganic polyphosphate-based energy regeneration system. In certain embodiments, the invention includes a cell-free expression system where the cellular energy source, ATP, is regenerated from inorganic polyphosphate using a dual enzyme system. In this embodiment, this dual enzyme system may include thermostable Adenosyl Kinase, and / or Polyphosphate Kinase enzymes.
Owner:NATURES TOOLBOX INC

Transient inhibition of adenosine kinase as an Anti-epileptogenesis treatment

Methods of anti-epileptogenesis treatment in which adenosine kinase (ADK) activity or expression is inhibited only transiently to provide a long-term benefit to a non-epileptic or epileptic subject. In an exemplary method, a therapeutically effective amount of an ADK inhibitor may be administered to a human non-epileptic subject over a finite, predetermined treatment period having a duration of less than two months. The non-epileptic subject may have sustained a precipitating event with a known risk to trigger latent development of an acquired form of epilepsy. Administration of the ADK inhibitor to the subject may be stopped at the end of the treatment period for at least the longer of (i) six months and (ii) ten times the duration of the treatment period. The step of administering may reduce the chance of the subject having seizures caused by the acquired form of epilepsy for an extended period following the end of the treatment period.
Owner:LEGACY EMANUEL HOSPITAL & HEALTH CENT

High-yield glutathione pichia pastoris strain G3-SF and application thereof

ActiveCN112779173AIncrease energy supplyEnhance energy supply and restructure metabolic pathwaysFungiTransferasesHeterologousPichia pastoris
The invention discloses a high-yield glutathione pichia pastoris strain G3-SF and an application thereof. Pichia pastoris GS115 is taken as a host, Scgsh1 and Scgsh2 genes from saccharomyces cerevisiae are subjected to heterologous expression, excessive production of GSH is obtained, and an engineering bacterium is named as G3. On the basis, heterologous expression is derived from a saccharomyces cerevisiae adenosine kinase Scadk1 gene and a streptococcus sanguis derived from a codon optimized StgshF gene, and aims to enhance energy supply in an engineering bacterium fermentation process and reconstruct a synthesis path of GSH. The maximum yield of glutathione at a shake flask level can reach (527.14+ / -17.92) mg / L, and the intracellular glutathione yield is (19.96+ / -0.05) mg / L / OD. The constructed engineering bacterium G3-SA is fermented in a 5L fermentation tank, the highest yield of glutathione in 56h is 5950mg / L, the intracellular glutathione yield is 25.54 mg / L / OD, and a new thought is provided for industrial production of GSH.
Owner:JIANGNAN UNIV

Method for preparing triphosadenine by immobilized enzyme method

The invention relates to the field of a biological technology, in particular to a method for preparing triphosadenine by an immobilized enzyme method. The method particularly comprises the following steps: (1) preparing ATP production enzyme; (2) immobilizing the ATP production enzyme; and (3) separating products. The ATP can be synthesized by adopting three kinds of ATP production enzyme such asadenosine kinase (EC 2.7.1.20, Ark), adenylate kinase (EC 2.7.4.3, Adk) and polyphosphoric acid-adenylate phosphotransferase (EC 2.7.4.-, Pap) and only through two-step enzymatic reaction, the reaction process is simple, the reaction is easy to control and the product quality is more stable; the ATP is prepared by an immobilized enzyme catalysis method, the immobilized enzyme can be used continuously and repeatedly for many times, and the production cost is greatly reduced; meanwhile, introduction of a large amount of pigment and other types of nucleotide impurities caused by the use of yeastis avoided and purification is facilitated; and the method is suitable for producing the ATP on a large scale.
Owner:美亚药业海安有限公司

AMP phosphotransferase mutant, coding gene thereof and application of AMP phosphotransferase mutant in ATP synthesis

The invention discloses an AMP (adenosine monophosphate) phosphotransferase mutant, a coding gene thereof and application of the AMP phosphotransferase mutant in ATP (adenosine triphosphate) synthesis. The amino acid sequence of the mutant is obtained by carrying out one or more mutations on a sequence shown as SEQ: ID: NO: 1. The mutation site of the gene comprises one or more mutation sites in the 124 site (A124L), the 312 site (G312M) and the 393 site (F393K). The invention further provides a composite biocatalyst containing adenosine kinase and the AMP phosphotransferase mutant and application of the composite biocatalyst in ATP synthesis. The mutant is higher in enzyme activity, higher in stability and higher in ATP generation ratio, the repeated batch after immobilization is larger than 100, the cost for producing ATP through a whole enzyme method can be further reduced, the whole adenosine phosphorylation ATP synthesis reaction can be completed by reducing the number of enzyme types to 2, and large-scale industrial application is facilitated.
Owner:美邦美和生物科技有限公司

Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing an adenosine kinase

ActiveUS7141434B2Organic active ingredientsPeptide/protein ingredientsIl 4 receptorSurrogate analyte
The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize an adenosine kinase as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
Owner:RIGEL PHARMA

Application of adenosine kinase inhibitor in preparation of anti-coronavirus preparation

The invention discloses an application of an adenosine kinase inhibitor in preparation of an anti-coronavirus preparation. The adenosine kinase inhibitor is 5-iodo tubercle bacillus. It is found for the first time that 5-iodo tubercle bacillus can obviously inhibit the activity of coronavirus-dependent RNA polymerase and shows good resistance to SARS-CoV-2 excision enzyme, and then application of 5-iodo tubercle bacillus in preparation of a coronavirus-dependent RNA polymerase antagonist and anti-coronavirus drugs is provided. The invention provides a small molecule compound capable of effectively resisting the coronavirus, so that the treatment means of the coronavirus is further enriched.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI

Enzyme of cordyceps sinensis hirsutella sinensis anabolic adenylic acid, gene and application of enzyme

The invention relates to an enzyme of metabolic adenine nucleotide synthesized by cordyceps sinensis hirsutella sinensis from bailing producing bacteria to participate in adenosine starting, gene coding the enzyme and an application of the enzyme. The adenosine kinase amino acid sequence is shown as SEQ ID No (sequencer identifier number).1, and the coding gene correspondingly has the nucleotide sequence shown as SEQ ID No .2. The metabolic pathway of the adenosine synthesized adenine nucleotide is detailedly studied in the principle aspect, cloning DNA (deoxyribonucleic acid) containing the nucleotide sequence provided by the invention can be used for being transferred into engineering bacteria by transduction, conversion and combination methods, high expression of host adenine nucleotide is given through regulating the adenine nucleotide biosynthetic gene expression, an effective path is provided for the yield increase of the adenine nucleotide, and great application prospects are realized.
Owner:ZHEJIANG UNIV OF TECH +1

4-anilinoquinazoline derivatives with adenosine-kinase inhibitor properties

The present invention relates to the use of 4-anilinoquinazoline derivatives as adenosine-kinase inhibitors. The present invention also relates to a method for protecting tissues and organs like heart, brain and kidneys affected by ischemia, and for treating heart insufficiency, myocardium infarct, arrhythmia, arterial hypertension, atherosclerosis, coronary artery restenosis after angioplasty, chronic renal insufficiency, cerebral vascular accident, and chronic inflanunatory diseases (e.g., rheumatoid arthritis). The present invention also relates to the compound 6,7-dimethoxy-4-(3′-N′,N′-dimethylaminoanilino)quinazoline, or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising it and use of such compound in the manufacture of a medicament for treating or preventing diseases or conditions that are benefited from the adenosine-kinase inhibition.
Owner:UNIV ESTADUAL DE CAMPINAS UNICAMP

High-yield glutathione pichia pastoris strain G3-SA and application thereof

The invention discloses a high-yield glutathione pichia pastoris strain G3-SA and application thereof. Pichia pastoris GS115 is used as a host, Scgsh1 and Scgsh2 genes derived from saccharomyces cerevisiae are heterologously expressed, GSH overproduction is obtained, and an engineering bacterium is named as G3; and on the basis, adenosine kinase Scadk1 derived from saccharomyces cerevisiae are heterologously expressed to enhance energy supply in the fermentation process. The highest yield of glutathione in a shake flask can reach (465.50 + / -29.90) mg / L, and the yield of intracellular glutathione is (16.87+ / -0.63) mg / L / OD. The engineering bacterium G3-SA is subjected to fermentation in a 5L fermentation tank, the highest yield of glutathione is 4810 mg / L within 56 h, the yield of intracellular glutathione is 19.87 mg / L / OD, and a new thought is provided for industrial production of GSH.
Owner:JIANGNAN UNIV

Biomarker for predicting susceptibility risk of noise-induced hearing loss and application thereof

The invention discloses a biomarker for predicting the susceptibility risk of noise-induced hearing loss and application thereof. The biomarker is an SNP (Single Nucleotide Polymorphism) site rs1396793 in a 5' UTR region of an AAK1 (Adenosine Adenosine Kinase 1) gene. By detecting the rs1396793 genotype in the 5' UTR region of the AAK1 gene of the testee, whether the testee is a susceptible individual with noise-induced hearing loss or not is judged. According to the present invention, the rs1396793 in the 5' UTR region of the AAK1 gene is the NIHL tolerance mutation, and the rs1396793 mutant type-carrying homozygous individual has significant tolerance to noise, and the SNP mutation can be used for early screening of NIHL susceptible high risk groups, providing employment selection and noise protection guidance, helping clarification of the NIHL pathogenic mechanism, developing of the new targeting intervention treatment drug, and providing the new strategy for NIHL prevention and treatment.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Method for synthesizing D-psicose by combining phosphonase and ATP regeneration system

The invention discloses a method for improving the equilibrium conversion rate of D-psicose synthesized by taking D-glucose as a substrate through combination of phosphonase and an ATP regeneration system. D-psicose is prepared by taking D-glucose as a raw material through recombinant escherichia coli construction, wet thallus preparation and whole-cell catalytic reaction in sequence. The recombinant escherichia coli is used for simultaneously expressing the glucokinase, the 6-phosphoglucose isomerase, the D-psicose-6-phospho-3 epimerase, the D-psicose-6-phosphate-phosphoesterase and the adenosine kinase, and the recombinant escherichia coli is used for simultaneously expressing the glucokinase, the 6-phosphoglucose isomerase, the D-psicose-6-phosphate-phosphoesterase and the adenosine kinase. Wherein the construction process of the recombinant escherichia coli comprises introduction of an ATP regeneration system. According to the method, phosphoenzyme and an ATP regeneration system are combined, so that the conversion rate of synthesizing D-psicose from D-glucose is increased, and the addition of exogenous ATP is reduced. The method has the characteristics of simple preparation process, high product conversion rate, greenness and economy, and can be used for industrial production.
Owner:湖南成大生物科技有限公司

4-Anilinequinazolines with adenosine-kiase inhibitor properties

The present invention relates to the use of 4-anilinoquinazoline derivatives as adenosine-kinase inhibitors. The present invention also relates to a method for protecting tissues and organs like heart, brain and kidneys affected by ischemia, and for treating heart insufficiency, myocardium infarct, arrhythmia, arterial hypertension, atherosclerosis, coronary artery restenosis after angioplasty, chronic renal insufficiency, cerebral vascular accident, and chronic inflanunatory diseases (e.g., rheumatoid arthritis). The present invention also relates to the compound 6,7-dimethoxy-4-(3′-N′,N′-dimethylaminoanilino)quinazoline, or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising it and use of such compound in the manufacture of a medicament for treating or preventing diseases or conditions that are benefited from the adenosine-kinase inhibition.
Owner:UNIV ESTADUAL DE CAMPINAS UNICAMP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products